Vanda Pharmaceuticals held a conference call Conference call to discuss positive Phase III results for Tasimelteon for the treatment of a non-24 hour disorder was held on December 18 at 9 am and has a replay available from 11 am on December 18 through December 25. Webcast Link
News For VNDA From The Last 14 Days
Check below for free stories on VNDA the last two weeks.
Vanda Pharmaceuticals price target raised to $19 from $9 at JMP Securities JMP Securities has increased confidence in Vanda's tasimelteon after reviewing data and receiving feedback from doctors. The firm keeps an Outperform rating on the stock.